Advice
in the absence of a submission from the holder of the marketing authorisation:
safinamide (Xadago®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of adult patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of Levodopa alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice68KB (PDF)
Medicine details
- Medicine name:
- safinamide (Xadago)
- SMC ID:
- 1259/17
- Indication:
- for the treatment of adult patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of Levodopa alone or in combination with other PD medicinal products in mid-to-late stage fluctuating patients.
- Pharmaceutical company
- Zambon SpA
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 June 2017